Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Public ClinicalTrials.gov record NCT05733598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Study identification
- NCT ID
- NCT05733598
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- RP2 Biological
- Bevacizumab Biological
- Atezolizumab Biological
- Durvalumab Biological
- RP2 Monotherapy Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2024
- Primary completion
- Nov 30, 2027
- Completion
- Jun 30, 2028
- Last update posted
- Apr 1, 2026
2024 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla | California | 92037 | Recruiting |
| Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics) | Miami | Florida | 33136 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14236 | Recruiting |
| Montefiore Medical CenterMontefiore Medical Park | The Bronx | New York | 10461 | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| The West Clinic | Germantown | Tennessee | 38138 | Recruiting |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | Recruiting |
| Houston Methodist Hospital Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05733598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05733598 live on ClinicalTrials.gov.